What is MYMX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MYMX?

P/E (TTM) is n/a and 52-week range is €0.00 to €0.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MYMX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MYMX?

The company profile lists revenue (TTM) near $523K, net income (TTM) near -$1.14B, EPS (TTM) near -€70.19 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Mymetics Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Epalinges, Vaud, CH, 150K shares outstanding, ISIN US62856A3005 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Mymetics Corp

$MYMX

Health Care · Biotechnology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Mymetics Corp. is a vaccine company, which focuses on the research and development of next generation vaccines for infectious and life disabling diseases. The firm is focused on developing vaccines for infectious diseases. The firm has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.

Employees

Website

www.mymetics.com/

IPO

1995-02-10

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

OTC MARKETS

ISIN

US62856A3005

Headquarters

Epalinges, Vaud, CH

Shares outstanding

150K

NAICS sector

Manufacturing

Browse other companiesFree AI scores and summaries for more stocks